Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

Modern Dental Group Announces 2024 Third Quarter Operational Update – Biotech Investments

EQS Newswire / 29/11/2024 / 09:00 UTC+8 (28 November 2024, Hong Kong) – Modern Dental Group Limited (“Modern Dental” or “the Group“, stock code: 03600.HK),

November 30, 2024

Why Do Kids of Smokers Wheeze Less When Mom Took Vitamin C During Pregnancy?

Improved airway function appeared to mediate the association between vitamin C supplementation and wheeze in kids whose mothers smoked and received vitamin C during pregnancy,

April 9, 2024

The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California – Psychedelic Alpha

“A response can be expected within 30 business days after the Panel meeting”, according to the Attorney General’s office. That’s up to six weeks without

January 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.